Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Int. braz. j. urol ; 42(1): 139-145, Jan.-Feb. 2016. graf
Artigo em Inglês | LILACS | ID: lil-777321

RESUMO

ABSTRACT Purpose To investigate whether intracavernosal injection of short hairpin RNA for IGFBP-3 could improve erectile function in streptozotocin-induced diabetic rats. Materials and methods After 12 weeks of IGFBP-3 short hairpin RNA injection treatment, intracavernous pressure responses to electrical stimulation of cavernous nerves were evaluated. The expression of IGFBP-3 and IGF-1 at mRNA and protein levels were detected by quantitative real-time PCR analysis and Western blot, respectively. The concentration of cavernous cyclic guanosine monophosphate was detected by enzyme-linked immunosorbent assay. Results At 12 weeks after intracavernous administration of IGFBP-3 shRNA, the cavernosal pressure was significantly increased in response to the cavernous nerves stimulation compared to the diabetic group (P<0.05). Cavernous IGFBP-3 expression at both mRNA and protein levels was significantly inhibited. At the same time, cavernous IGF-1 expression was significantly increased in the IGFBP-3 shRNA treatment group compared to the diabetic group (P<0.01). Cavernous cyclic guanosine monophosphate concentration was significantly increased in the IGFBP-3 shRNA treatment group compared to the diabetic group (P<0.01). Conclusions Gene transfer of IGFBP-3 shRNA could improve erectile function via the restoration of cavernous IGF-1 bioavailability and an increase of cavernous cGMP concentration in the pathogenesis of erectile dysfunction in streptozotocin-induced diabetic rats.


Assuntos
Animais , Masculino , Pênis/efeitos dos fármacos , Proteína 3 de Ligação a Fator de Crescimento Semelhante à Insulina/farmacocinética , RNA Interferente Pequeno/farmacocinética , Diabetes Mellitus Experimental/fisiopatologia , Disfunção Erétil/fisiopatologia , Disfunção Erétil/tratamento farmacológico , Fator de Crescimento Insulin-Like I/análise , Fator de Crescimento Insulin-Like I/efeitos dos fármacos , Ensaio de Imunoadsorção Enzimática , Disponibilidade Biológica , Distribuição Aleatória , Western Blotting , Reprodutibilidade dos Testes , Ratos Wistar , Estreptozocina , Diabetes Mellitus Experimental/complicações , Reação em Cadeia da Polimerase em Tempo Real , Disfunção Erétil/etiologia , Injeções
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA